[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586614":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":51,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":59,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"China National Center for Cardiovascular Diseases","OTHER_GOV",[8,12],{"label":9,"type":10,"description":11,"interventionNames":11},"Control group: isolated CABG","NO_INTERVENTION",null,{"label":13,"type":14,"description":11,"interventionNames":15},"Sacubitril\u002Fvalsartan therapy after isolated CABG","EXPERIMENTAL",[16],"Drug: sacubitril\u002Fvalsartan",[18],{"type":19,"name":20,"description":13,"armGroupLabels":21,"otherNames":11},"DRUG","sacubitril\u002Fvalsartan",[13],[23],{"name":24,"affiliation":5,"role":25},"Wei Zhao","STUDY_CHAIR",[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Lianxin Chen, M.D.","CONTACT","010-88322265","chenlianx1@163.com",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Beijing","Beijing Municipality","100037","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":28,"role":29,"phone":48,"phoneExt":11,"email":31},"01088322265",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[52,55],{"name":53,"class":54},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",{"name":56,"class":54},"Chinese Academy of Medical Sciences","100586614","phase-4-treatment-of-moderate-ischemic-mitral-regurgitation-in-patients-with-coronary-artery-disease-100586614",false,"NCT06917664","Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease","Inclusion Criteria:\n\n1. Fully informed and voluntarily signed informed consent;\n2. Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC\u002FEACTS Guidance Standards )\n\nExclusion Criteria:\n\n1.Symptomatic hypotension and\u002For a SBP \\\u003C 100 mmHg at screening; 2.Estimated GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2; 3.Serum potassium \\> 5 mmol\u002FL at screening; 4.History of angioedema or unacceptable side effects while receiving ACE inhibitors or ARBs; 5.Patients receiving mitral valve intervention at the same time, or have participated in other clinical trials, or are unwilling to participate in this study.","ALL","18 Years",{"count":66,"type":67},220,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","This study aims to evaluate the effect of angiotensin receptor\u002Fneprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.",[73,74,75],"Coronary Artery Disease","Ischemic Mitral Regurgitation","Angiotensin Receptor\u002FNeprilysin Inhibitor",[77,78,79],"coronary artery disease","ischemic mitral regurgitation","angiotensin receptor\u002Fneprilysin inhibitor","2025-08-20",{"date":82,"type":83},"2025-08-27","ACTUAL",{"date":85,"type":83},"2025-06-05",{"date":87,"type":67},"2027-06",{"name":5,"class":6},1]